Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Newgam, NCT01012323 / 2009-011434-10: A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

Completed
3
51
US
NewGam, Human normal immunoglobulin
Octapharma, Premier Research Group plc
Primary Immunodeficiency Diseases
06/12
06/12
NGAM-05, NCT01313507 / 2011-005015-82: High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

Completed
3
21
US
NewGam
Octapharma
Primary Immunodeficiency Disease
09/12
09/12
NCT01349790 / 2009-014589-24: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

Completed
3
40
Europe
NewGam
Octapharma
Primary Thrombocytopenia
07/13
07/13
NCT00033293: Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Completed
3
53
Canada, US, RoW
Clinical Observation, observation, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Therapeutic Immune Globulin, BayGam, Gamimune N, Gamma Globulin, Gammagard S/D, Gammar-P, IgIV, Immune Globulin, Immune Globulin Intravenous, Immune Globulin IV, Iveegam EN, Panglobulin, Panzyga, Polygam S/D, Sandoglobulin, Therapeutic Immunoglobulin, Venoglobulin-I, Venoglobulin-S, WinRho SDF
Children's Oncology Group, National Cancer Institute (NCI)
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
12/13
12/22
Panzyga-CIDP, NCT03166527: Panzyga in CIDP Administered at Different Infusion Rates

Unknown status
3
30
Canada
Immune Globulin 10% Intravenous Solution, Panzyga IVIG
Vera Bril
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/18
12/18
NCT02638207 / 2015-005443-14: Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy

Completed
3
142
Europe, Canada, RoW
NewGam, Panzyga
Octapharma
Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
09/19
09/19
2019-004375-40: Study for the evaluatiion of Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (“PRO-SID” study) Studie zur Ermittlung der Wirksamkeit und Sicherheit von Panzyga in der primären Infektionsprophylaxe bei Patienten mit chronischer lymphatischer Leukämie ("PRO-SID"-Studie)

Not yet recruiting
3
450
Europe, RoW
Panzyga, [NA], Solution for infusion, Panzyga
Octapharma Pharmazeutika Produktionsges.m.b.H., OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H., Octapharma Pharmazeutika Produktionsges.m.b.H.
Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia, Prophylaxis to prevent infection in patients with a type of cancer that starts in bone marrow and then go into the blood, Diseases [C] - Cancer [C04]
 
 
PROSID, NCT04502030: Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Recruiting
3
240
Europe, US, RoW
Panzyga, Placebo
Octapharma
Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
10/25
10/25
NGAM-13, NCT04508530 / 2020-000867-21: Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

Active, not recruiting
3
70
Europe, US
Panzyga, Placebo
Octapharma
Pediatric Acute-Onset Neuropsychiatric Syndrome
06/24
06/24
NGAM-11, NCT04929236 / 2021-003200-40: Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Recruiting
3
30
US
Panzyga
Octapharma
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
06/26
06/26
NCT01225276 / 2009-017805-13: Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

Terminated
2/3
2
NA
NewGam 10%, Placebo, 0.9% saline solution
Octapharma
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
10/12
10/12

Download Options